{
    "nct_id": "NCT05038332",
    "official_title": "A Phase II Randomized Trial of Moderate Versus Ultra-hypofractionated Post-prostatectomy Radiation Therapy",
    "inclusion_criteria": "* Men age ≥ 18 with histologically confirmed prostate cancer after radical prostatectomy with a PSA ≥ 0.1 ng/mL\n* Interval between prostatectomy and planned radiation therapy start date ≥ 6 months\n* KPS ≥ 70\n* Patients with equivocal pelvic lymph nodes on imaging are eligible if the nodes are ≤ 1.5 cm in the short axis (equivocal evidence of metastatic disease outside of the pelvis on standard imaging requires documented negative biopsy)\n* Ability to complete the EPIC-26 quality of life questionnaire\n* Ability to obtain tissue from radical prostatectomy specimen for review by Michigan Medicine Pathology\n* Ability to understand and the willingness to sign a written informed consent.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior history of pelvic radiation therapy\n* History of moderate/severe or active Crohn's disease or ulcerative colitis\n* History of bladder neck or urethral stricture\n* Evidence of distant metastatic disease or nodal involvement beyond the common iliac vessels\n* Initiation of androgen deprivation therapy with a LHRH / GnRH agonist or antagonist greater than 6 months prior to enrollment or receipt of any non-LHRH / GnRH agonist or antagonist androgen deprivation or anti-androgen therapy\n* History of another invasive malignancy within the previous 3 years except for adequately treated squamous or basal cell skin cancer\n* Any condition that in the opinion of the investigator would preclude participation in this study",
    "miscellaneous_criteria": ""
}